HAE
12 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema (NCT05121376) | BioMarin Pharmaceutical | 2022-02-15 |
| Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies (NCT04933721) | BioCryst Pharmaceuticals | 2021-07-23 |
| Biomarker for Hereditary AngioEdema Disease (NCT03029728) | CENTOGENE GmbH Rostock | 2018-08-20 |
| A Long Term Safety Study of BCX7353 in Hereditary Angioedema (NCT03472040) | BioCryst Pharmaceuticals | 2018-02-16 |
| Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema (NCT02670720) | BioCryst Pharmaceuticals | 2015-12-01 |
| 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks (NCT02303626) | BioCryst Pharmaceuticals | 2014-12-17 |
| Oral Berotralstat Expanded Access Program (NCT04428632) | BioCryst Pharmaceuticals |
Track HAE automatically
Every clearance here is in the API, with alerts when new ones post.